GB-4362 / Generate Biomedicines - LARVOL DELTA

GB-4362, an MMAE-neutralizing antibody, in combination with enfortumab vedotin (EV) and pembrolizumab in advanced urothelial cancer: Phase 1 trial-in-progress (ESMO 2026) - No abstract available

Combination therapy • Metastases • P1 data • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Recent Progress (PRNewswire) - "In oncology, Generate's GB-4362 (MMAE neutralizer) program has activated clinical trial sites, and the first patient is expected to be dosed in mid-2026...Generate's GB-5267 (MUC16 armored CAR T) program, developed in collaboration with Roswell Park Comprehensive Cancer Center, is expected to dose the first patient in the second half of 2026 in a Phase 1 clinical trial in solid tumors, initially targeting ovarian cancer."

Platinum resistant • Trial status • Ovarian Cancer • Urothelial Cancer

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer (clinicaltrials.gov) - P1 | N=37 | Recruiting | Sponsor: Generate Biomedicines | Not yet recruiting ➔ Recruiting

Enrollment open • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer (clinicaltrials.gov) - P1 | N=37 | Not yet recruiting | Sponsor: Generate Biomedicines

New P1 trial • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

The biotech estimates $15 million of the proceeds will be needed to take GB-4362 and GB-5267 into the clinic. (FierceBiotech)

Financing • Solid Tumor